Sarepta jumps into the CRISPR fray with Duke gene-editing pact – Boston Business Journal
Boston Business Journal |
Sarepta jumps into the CRISPR fray with Duke gene-editing pact
Boston Business Journal Sarepta (Nasdaq: SRPT) said it had reached an agreement to exclusively license technology related to CRISPR/Cas9 from Duke University. Researchers there, led by Dr. Charles Gersbach, have shown that the technology can be used in mice to remove … Expanding its preclinical attack on Duchenne MD, Sarepta grabs a license for Duke's CRISPR tech Sarepta Therapeutics (SRPT) Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR … Sarepta inks research collaboration with Duke University for use of gene editing technology to restore dystrophin … |
